The reiteration of an Equal-Weight rating suggests that Morgan Stanley believes Jazz Pharmaceuticals is fairly valued at its current price. The maintained price target of $187 indicates that the analyst does not foresee significant price movement in the short term. This is likely to have a neutral impact on the stock's price.